Product Overview
[Drug Name]
Generic Name: Omeprazole Enteric-Coated Capsules
Trade Name: Xiangjiang Omeprazole Enteric-Coated Capsules 20mg*14 capsules/bottle
Pinyin Code: XiangJiang AoMeiLaZuoChangRongJiaoNang 20mg*14Li/Ping
[Main Ingredient]
The main ingredient is omeprazole. Chemical name: S-methoxy-2-(((4-methoxy-3,S-dimethyl-2-pyridyl)methyl)sulfinyl)-1H-benzimidazole.
[Properties]
This product is a white or off-white capsule.
[Indications/Main Functions]
Indicated for gastric ulcers, duodenal ulcers, stress ulcers, reflux esophagitis, and Zollinger-Ellison syndrome (gastrinoma).
[Specifications]
20mg*14 capsules/bottle
[Dosage and Administration]
For oral use; do not chew. 1. Peptic ulcer: 20 mg (1 tablet) once daily, 1-2 times daily. Take it in the morning or once in the morning and evening. The treatment course for gastric ulcer is usually 4-8 weeks. 2. Reflux esophagitis: 20-60 mg (1-3 tablets) once daily, 1-2 times daily. Take it in the morning or once in the morning and evening. The treatment course is usually 4-8 weeks. 3. Zollinger-Ellison syndrome: 60 mg (3 tablets) once daily. The total daily dose can be adjusted to 20-120 mg (1-6 tablets) depending on the condition. If the total daily dose exceeds 80 mg (4 tablets), take it in two doses.
[Adverse Reactions]
Omeprazole enteric-coated capsules are well tolerated. Common adverse reactions include diarrhea, headache, nausea, abdominal pain, flatulence, and constipation. Elevated serum aminotransferases (ALT, AST), rash, dizziness, drowsiness, and insomnia may occur occasionally. These adverse reactions are generally mild. May disappear spontaneously. It is dose-independent. No serious adverse reactions have been observed with long-term treatment. However, in some cases, gastric mesenchymal cell hyperplasia and atrophic gastritis may occur.
[Contraindications]
Not yet known.
[Drug Interactions]
This product may delay the elimination of drugs metabolized by the liver, such as diazepam, phenytoin, warfarin, and nifedipine. When used with these drugs, the dosage of the latter should be reduced.
[Precautions]
1. When treating gastric ulcers, the possibility of ulcerative gastric cancer should be ruled out first, as this product may alleviate symptoms and delay treatment. 2. Use with caution in patients with hepatic and renal insufficiency. 3. This product comes in enteric-coated capsules. Be careful not to chew them when taking to avoid premature release of the drug in the stomach, which could affect efficacy.
[Children's Use]
Follow your doctor's instructions.
[Elderly Use]
This product has not been tested for this purpose and no reliable references are available.
[Overdose]
Not yet known.
[Pharmacology and Toxicology]
Proton pump inhibitor. This drug is a lipid-soluble, weakly alkaline drug that tends to concentrate in acidic environments. Therefore, after oral administration, it is specifically distributed in the secretory tubules of gastric mucosal parietal cells, where it is converted into its active form, the sulfenamide, in this highly acidic environment. It then irreversibly binds to residues of the H+, K+-ATPase (also known as the proton pump) in the gastric cell secretory membrane via a monosulfide bond, forming a sulfenamide-proton pump complex. This inhibits the enzyme's activity, blocking the final step in gastric acid secretion. Therefore, this drug has a strong and long-lasting inhibitory effect on gastric acid secretion caused by various factors.
